[HTML][HTML] KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer
J Cicenas, K Kvederaviciute, I Meskinyte… - Cancers, 2017 - mdpi.com
Pancreatic cancer is a disease that has a very high fatality rate and one of the highest
mortality ratios among all major cancers, remaining the fourth leading cause of cancer …
mortality ratios among all major cancers, remaining the fourth leading cause of cancer …
[HTML][HTML] Pathogenesis of pediatric B‑cell acute lymphoblastic leukemia: Molecular pathways and disease treatments
FL Huang, EC Liao, CL Li, CY Yen… - Oncology …, 2020 - spandidos-publications.com
B‑cell acute lymphoblastic lymphoma (B‑ALL) is a disease found mainly in children and in
young adults. B‑ALL is characterized by the rapid proliferation of poorly differentiated …
young adults. B‑ALL is characterized by the rapid proliferation of poorly differentiated …
[HTML][HTML] Histone H3K27M mutation overrides histological grading in pediatric gliomas
A Mosaab, M El-Ayadi, EN Khorshed, N Amer… - Scientific reports, 2020 - nature.com
Pediatric high-grade gliomas (HGG) are rare aggressive tumors that present a prognostic
and therapeutic challenge. Diffuse midline glioma, H3K27M–mutant is a new entity …
and therapeutic challenge. Diffuse midline glioma, H3K27M–mutant is a new entity …
[HTML][HTML] Small molecule KRAS agonist for mutant KRAS cancer therapy
Background Lung cancer patients with KRAS mutation (s) have a poor prognosis due in part
to the development of resistance to currently available therapeutic interventions …
to the development of resistance to currently available therapeutic interventions …
Childhood cancer care in the Middle East, North Africa, and West/Central Asia: a snapshot across five countries from the POEM network
Abstract Background The Pediatric Oncology East and Mediterranean (POEM) network,
through this report, provides a snapshot view of an expected child's treatment journey in five …
through this report, provides a snapshot view of an expected child's treatment journey in five …
Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
LP Liu, AL Zhang, M Ruan, LX Chang, F Liu… - Cancer …, 2020 - Wiley Online Library
Background The prognosis of children with acute monocytic leukemia (AML‐M5) remains
unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic …
unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic …
Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center
We performed a retrospective analysis of 1415 acute lymphoblastic leukemia children
diagnosed between January 2000 and December 2016 at Children Welfare Teaching …
diagnosed between January 2000 and December 2016 at Children Welfare Teaching …
High-selectivity single-nucleotide variant capture technology based on the DNA reaction network
The extremely low abundance of circulating tumor DNA in blood samples has limited the
development of liquid biopsy techniques for the early diagnosis of major diseases. In this …
development of liquid biopsy techniques for the early diagnosis of major diseases. In this …
High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR‐ABL1‐like acute lymphoblastic leukemia
JW Lee, Y Kim, B Cho, S Kim, PS Jang, J Lee… - Cancer …, 2020 - Wiley Online Library
Introduction Recent advances in genetic analysis have led to the discovery of novel genetic
subtypes of precursor B‐cell acute lymphoblastic leukemia (B‐ALL) with prognostic …
subtypes of precursor B‐cell acute lymphoblastic leukemia (B‐ALL) with prognostic …
[HTML][HTML] Spectrum and clinical features of gene mutations in Chinese pediatric acute lymphoblastic leukemia
D Shen, L Liu, X Xu, H Song, J Zhang, W Xu, F Zhao… - BMC pediatrics, 2023 - Springer
Purpose The 5-year survival rate of children with acute lymphoblastic leukemia (ALL) is 85–
90%, with a 10–15% rate of treatment failure. Next-generation sequencing (NGS) identified …
90%, with a 10–15% rate of treatment failure. Next-generation sequencing (NGS) identified …